Regulus Therapeutics Inc. is a clinical stage pharmaceutical company in the United States, focused on discovering and developing drugs that treat a variety of diseases by targeting microRNAs. Its current product candidates include an anti-miR for Alport syndrome and an anti-miR that may help treat autosomal dominant polycystic kidney disease. Regulus also has a range of preclinical drug products in development.